A
Amylyx Pharmaceuticals, Inc. (AMLX)
NMS – Real vaqt narxi. Valyuta: USD
17.79
+0.35 (2.01%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
17.79
0.00 (0.00%)
Bozordan keyin: Jun 26, 2026, 5:27 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
17.79
+0.35 (2.01%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
17.79
0.00 (0.00%)
Bozordan keyin: Jun 26, 2026, 5:27 PM EDT
Amylyx Pharmaceuticals, Inc. klinik tadqiqot bosqichidagi farmatsevtika kompaniyasi bo'lib, Qo'shma Shtatlarda neyrodegenerativ kasalliklar va endokrin kasalliklar uchun davolash usullarini kashf qilish va ishlab chiqish bilan shug'ullanadi. Kompaniya Avexitide-ni taqdim etadi, bu birinchi sinf glukagon-o'xshash peptid-1, yoki GLP-1 retseptorlari antagonistidir, bu post-bariatrik gipoglikemiya va tug'ma giperinsulinizmni davolash uchun 3-bosqichli klinik sinovda. Kompaniya shuningdek, natriy fenilbutirat va taurursodiolning og'iz orqali qabul qilinadigan, doimiy dozali kombinatsiyasi bo'lgan AMX0035ni ishlab chiqmoqda, bu Wolfram sindromini davolash uchun 2-bosqichli klinik sinovda, shuningdek, progressiv supranuklear falajni davolash uchun 2b/3-bosqichli klinik sinovda; AMX0114, bu amiotrofik lateral sklerozni davolash uchun 1-bosqichli klinik sinovda; va post-bariatrik gipoglikemiya va boshqa kam uchraydigan kasalliklarni davolash uchun uzoq muddatli GLP-1 retseptorlari antagonisti. Bundan tashqari, u post-bariatrik gipoglikemiya va boshqa kam uchraydigan kasalliklarni davolash uchun GLP-1 retseptorlari antagonisti bo'lgan AMX0318ni ishlab chiqmoqda. Amylyx Pharmaceuticals, Inc. 2013 yilda tashkil etilgan va uning shtab-kvartirasi Kembrijda, Massachusets shtatida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Camille L. Bedrosian M.D. | Chief Medical Officer |
| Dr. Machelle Manuel Ph.D. | VP & Head of Global Medical Affairs |
| Mr. James M. Frates M.B.A. | Chief Financial Officer |
| Mr. Joshua B. Cohen | Co-Founder, Co-CEO & Director |
| Mr. Justin B. Klee | Co-CEO & Director |
| Mr. Tom Holmes | Chief Technical Operations Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-06-04 | 8-K | d128401d8k.htm |
| 2026-05-07 | 8-K | amlx-20260507.htm |
| 2026-05-07 | 10-Q | amlx-20260331.htm |
| 2026-04-23 | DEFA14A | amlx-defa14a-2026-additi.htm |
| 2026-04-23 | DEF 14A | amlx-20260422.htm |
| 2026-04-23 | ARS | amlx-ars-2026.pdf |
| 2026-03-24 | 8-K | d49067d8k.htm |
| 2026-03-03 | S-8 | d102493ds8.htm |
| 2026-03-03 | S-3ASR | d82596ds3asr.htm |
| 2026-03-03 | 8-K | amlx-20260303.htm |
| Ms. Gina M. Mazzariello J.D. | Chief Legal Officer & General Counsel |
| Ms. Linda A. Arsenault | Chief Human Resources Officer |
| Ms. Lindsey Allen | Head of Investor Relations & Communications |
| Ms. Tammy Sarnelli | Global Head of Regulatory Affairs |